New diabetes medications
Here are some new diabetes medications that have been approved by regulatory authorities in recent years:
- SGLT-2 inhibitors:
- Farxiga (dapagliflozin) - approved in 2014
- Invokana (canagliflozin) - approved in 2013
- Jardiance (empagliflozin) - approved in 2014
- Steglatro (ertugliflozin) - approved in 2017
- Zynquista (sotagliflozin) - approved in 2019
- GLP-1 receptor agonists:
- Trulicity (dulaglutide) - approved in 2014
- Victoza (liraglutide) - approved in 2010
- Saxenda (liraglutide) - approved in 2014 (for weight loss)
- Ozempic (semaglutide) - approved in 2017
- Wegovy (semaglutide) - approved in 2021 (for weight loss)
- DPP-4 inhibitors:
- Nesina (alogliptin) - approved in 2009
- Onglyza (saxagliptin) - approved in 2009
- Januvia (sitagliptin) - approved in 2006
- Tradjenta (linagliptin) - approved in 2011
- SGLT-1 inhibitors:
- Eperzan (efpeglenatide) - approved in 2020
- BGLP-1 receptor agonists:
- Exenatide (Byetta) - approved in 2005
- Lixisenatide (Adlyxin) - approved in 2016
- Insulin analogs:
- Tresiba (insulin degludec) - approved in 2014
- Basaglar (insulin glargine) - approved in 2014
- Lusduna (insulin glargine) - approved in 2020
- Other medications:
- Jardiance XR (empagliflozin) - approved in 2020 (extended-release formulation)
- Xultophy (insulin degludec and liraglutide) - approved in 2016
Please note that this is not an exhaustive list, and new medications are being developed and approved regularly. Additionally, the availability of these medications may vary depending on your location and healthcare provider. It's always best to consult with your healthcare provider to determine the best treatment plan for your specific needs.